Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

February 25, 2018

Study Completion Date

February 25, 2018

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Tideglusib

Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg

OTHER

Placebo

Administered orally after dispersion in approximately 100 ml of water

Trial Locations (3)

L8S 4K1

McMaster University, Offord Centre for Child Studies, Hamilton

N6A 5W9

University of Western Ontario, Lawson Health Research Institute, London

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

McMaster University

OTHER

collaborator

Western University, Canada

OTHER

collaborator

Unity Health Toronto

OTHER

collaborator

University of Toronto

OTHER

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT02586935 - Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter